Will work with University Hospital Southampton NHS Foundation Trust on the service
News
EU allows use of UCB’s anti-epileptic Vimpat in children
The European Commission has ruled that UCB’s anti-epileptic Vimpat can be used in children.
NICE nod for new Eylea indication
The National Institute for Health and Care Excellence (NICE) has issued a final positive recommendation for Bayer’s Eylea as a treatment for adults for the treatment of visual impairment due to myopic chorodial neovascularisation.
Sanofi’s Kevzara will be funded for NHS use
Some patients with rheumatoid arthritis living in England and Wales should get ‘routine’ NHS access to Sanofi’s Kevzara after cost regulators issued draft guidelines deeming the drug cost effective.
FDA warning on Intercept’s Ocaliva after patient deaths
US regulators have issued a safety communication warning of the risk for serious liver injury and death from incorrect dosing of Intercept Pharmaceuticals’ Ocaliva in patients with primary biliary cholangitis.
Join us at the London Marriott Hotel, Grosvenor Square for the event of the year!
The Awards Ceremony for Marketer & Communications Team of the Year will take place at the London Marriott Hotel, Grosvenor Square on Thursday 9 November.
90% of GP practices delivering good or outstanding care
Eighty-six percent of GP practices in England have been rated as ‘good’ by the Care Quality Commission’s following completion of its first full inspection programme of general practices.
Merck’s MS pill Mavenclad launched in the UK and Ireland
Merck’s Mavenclad is now available in the UK and Ireland to treat highly active relapsing multiple sclerosis in adults.
Bayer and Bradford Teaching Hospitals NHS FT open eye unit
Bradford Teaching Hospitals NHS Foundation Trust and Bayer have opened a new Macula Centre to expand and improve access to services for patients with wet Age-related Macular Degeneration (wet AMD), a leading cause of vision loss in adults.
Sanofi, Alnylam’s RNAi therapeutic smashes PhIII targets
An investigational RNAi therapeutic being developed by Sanofi Genzyme and Alnylam Pharmaceuticals has hit targets in a late stage trial involving patients with hereditary ATTR amyloidosis with polyneuropathy.
EU green light for Merck, Pfizer’s Bavencio
Adult patients with metastatic Merkel cell carcinoma (mMCC) in Europe stand to gain access to the first immunotherapy to treat the disease following regulatory approval of Merck and Pfizer’s Bavencio.
UK firms link to develop ADCs for cancer
UK groups Glythera and IONTAS are working together on the development of antibody drug conjugates for difficult-to-treat cancers.
Shire’s Intuniv hits targets in adult ADHD trial
Data from a Phase III study evaluating Shire’s Intuniv in Japan in adults with attention deficit hyperactivity disorder indicate that the drug could improve symptoms of the condition in this patient group.
EU green light for Novartis’ Rydapt
The European Commission has approved Novartis’ Rydapt to treat a certain form of acute myeloid leukaemia (AML) as well as three other rare diseases.
NICE backs use of Opdivo for lung cancer
Bristol-Myers Squibb’s Opdivo is being recommended by the National Institute for Health and Care Excellence to treat a certain form of lung cancer on the NHS in England, via the Cancer Drugs Fund.
